M&A Deal Summary

Lilly Acquires Loxo Oncology

On January 7, 2019, Lilly acquired life science company Loxo Oncology for 8.0B USD

Acquisition Highlights
  • This is Lilly’s 16th transaction in the Life Science sector.
  • This is Lilly’s largest (disclosed) transaction.
  • This is Lilly’s 19th transaction in the United States.
  • This is Lilly’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2019-01-07
Target Loxo Oncology
Sector Life Science
Buyer(s) Lilly
Deal Type Add-on Acquisition
Deal Value 8.0B USD
Advisor(s) Goldman Sachs (Financial)
Fenwick & West (Legal)

Target

Loxo Oncology

Stamford, Connecticut, United States
Loxo Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is based in Stamford, Connecticut.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lilly

Indianapolis, Indiana, United States
Category Company
Founded 1876
Sector Life Science
Employees43,000
Revenue 34.1B USD (2023)
DESCRIPTION
Entrance to Eli Lilly's campus in Indianapolis, Indiana.
Entrance to Eli Lilly's campus in Indianapolis, Indiana.

Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.

DEAL STATS #
Overall 23 of 34
Sector (Life Science) 16 of 27
Type (Add-on Acquisition) 17 of 27
State (Connecticut) 1 of 1
Country (United States) 19 of 29
Year (2019) 1 of 1
Size (of disclosed) 1 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-12-14 Hydra Biosciences - Pre-Clinical Pain Program

Cambridge, Massachusetts, United States

Hydra Biosciences, Inc. - Pre-Clinical Pain Program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-04-22 Eli Lilly - Antibiotics Brands & Manufacturing Facility

Indianapolis, Indiana, United States

Eli Lilly and Co. - Antibiotics Brands & Manufacturing Facility comprises Ceclor and Vancocin, as well as a manufacturing facility in Suzhou, China that produces Ceclor.

Sell $375M
Mergr

Product

Company

Legal